Open Access<p>A Multi-Element Expression Score Is A Prognostic Factor In Glioblastoma Multiforme</p>
Author(s) -
Junqi Li,
Qianting Wang,
Ying Nie,
Yun-Peng Xiao,
Tao Lin,
Ru-Jin Han,
Zhe Li,
Fan Yang,
Xiaohui Yuan,
Yueming Wang,
Jian Zhang,
You–Wen He,
HuaXin Liao
Publication year - 2019
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s228174
Subject(s) - medicine , oncology , immunotherapy , tumor microenvironment , antigen , temozolomide , radiation therapy , glioma , cancer , immunology , cancer research
Glioblastoma multiforme (GBM) is a highly malignant tumor of the central nervous system. Although primary GBM patients receive extensive therapies, tumors may recur within months, and there is no objective and scientific method to predict prognosis. Adoptive immunotherapy holds great promise for GBM treatment. However, the expression profiles of the tumor-associated antigens (TAAs) and tumor immune microenvironment (TME) genes used in immunotherapy of GBM patients have not been fully described. The present study aimed to develop a predictive tool to evaluate patient survival based on full analysis of the expression levels of TAAs and TME genes.